TY - JOUR
T1 - Melanoma tumor cell heterogeneity
T2 - A molecular approach to study subpopulations expressing the embryonic morphogen nodal
AU - Seftor, Elisabeth A.
AU - Seftor, Richard E.B.
AU - Weldon, Don S.
AU - Kirsammer, Gina T.
AU - Margaryan, Naira V.
AU - Gilgur, Alina
AU - Hendrix, Mary J.C.
PY - 2014
Y1 - 2014
N2 - As the frequency of melanoma increases, current treatment strategies are struggling to significantly impact patient survival. One of the critical issues in designing efficient therapies is understanding the composition of heterogeneous melanoma tumors in order to target cancer stem cells (CSCs) and drug-resistant subpopulations. In this review, we summarize recent findings pertinent to the reemergence of the embryonic Nodal signaling pathway in melanoma and its significance as a prognostic biomarker and therapeutic target. In addition, we offer a novel molecular approach to studying the functional relevance of Nodal-expressing subpopulations and their CSC phenotype.
AB - As the frequency of melanoma increases, current treatment strategies are struggling to significantly impact patient survival. One of the critical issues in designing efficient therapies is understanding the composition of heterogeneous melanoma tumors in order to target cancer stem cells (CSCs) and drug-resistant subpopulations. In this review, we summarize recent findings pertinent to the reemergence of the embryonic Nodal signaling pathway in melanoma and its significance as a prognostic biomarker and therapeutic target. In addition, we offer a novel molecular approach to studying the functional relevance of Nodal-expressing subpopulations and their CSC phenotype.
UR - http://www.scopus.com/inward/record.url?scp=84899738233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899738233&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2014.02.001
DO - 10.1053/j.seminoncol.2014.02.001
M3 - Article
C2 - 24787297
AN - SCOPUS:84899738233
SN - 0093-7754
VL - 41
SP - 259
EP - 266
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 2
ER -
